Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov;60(11):1537-1540.
doi: 10.1038/s41409-025-02684-1. Epub 2025 Aug 27.

Definition of relapse criteria in patients with rapidly progressive systemic sclerosis treated with autologous haemopoietic stem cell transplantation

Nicoletta Del Papa  1 , Myriam Labopin  2 , Manuela Badoglio  2 , Dominique Farge  3 , Jorg Henes  4 , John A Snowden  5 , Julia Spierings  6 , Claudia Iannone  7 , Tobias Alexander  8   9 ; SSc expert panelist group; Raffaella Greco  10
Collaborators, Affiliations

Definition of relapse criteria in patients with rapidly progressive systemic sclerosis treated with autologous haemopoietic stem cell transplantation

Nicoletta Del Papa et al. Bone Marrow Transplant. 2025 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: RG discloses honoraria for speaking from educational events supported by Biotest, Pfizer, and Magenta. JAS declares honoraria for speaking at educational events supported by Jazz, Gilead, Janssen, Mallinckrodt, Actelion, an advisory board by MEDAC, and is a member of IDMC for a trial supported by Kiadis Pharma. TA declares travel grants from Neovii and study support from Amgen. JH discloses consultancy for Miltenyi and Neovii. JS discloses research support from Boehringer Ingelheim and Miltenyi. None of the mentioned conflicts of interest were related to financing of the content of this manuscript. The other authors declare no conflicting interests.

Figures

Fig. 1
Fig. 1. Classification tree for Round 2 Delphi consensus on disease relapse after AHSCT in systemc sclerosis.
Illustration of the hierarchical classification process of disease relapse after AHSCT in systemic sclerosis. Starting from all evaluated criteria, items were first categorized by their appropriateness level based on median scores, then further classified according to their agreement level determined by response range distribution. mRSS modified Rodnan Skin Score, ILD Interstitial Lung Disease, FVC Forced Vital Capacity, DLCO Diffusing Capacity for Carbon Monoxide, CT Computed Tomography, GI Gastrointestinal, CRP C-Reactive Protein, ESR Erythrocyte Sedimentation Rate.
See this image and copyright information in PMC

References

    1. Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390:1685–99. - DOI - PubMed
    1. Fransen J, Popa-Diaconu D, Hesselstrand R, Carreira P, Valentini G, Beretta L, et al. Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Ann Rheum Dis. 2011;70:1788–92. - DOI - PubMed
    1. Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76:1327–39. - DOI - PubMed
    1. Sullivan KM, Majhail NS, Bredeson C, Carpenter PA, Chatterjee S, Crofford LJ, et al. Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2018;24:1961–4. - DOI - PMC - PubMed
    1. Duarte RF, Labopin M, Bader P, Basak GW, Bonini C, et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transpl. 2019;54:1525–52. - DOI - PubMed